Homepage Top Section2

An orally disintegrating tablet and a calcitonin gene-related peptide (CGRP) receptor antagonist, Vydrua got the marketing authorisation for acute treatment of migraine with or without aura, and prophylaxis

This treatment is meant for patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-negative) breast cancer patients who have earlier received a systemic therapy in

The drug will be indicated as an adjuvant treatment for NSCLC in adults with a high risk of recurrence with PD-L1≥50% and without EGFR mutant or ALK-positive NSCLC,

BenevolentAI is clinical-stage artificial intelligence (AI) enabled drug discovery company, while DNDi) is a not-for-profit research and development (R&D) organisation with focus on neglected diseases., The company focuses

Located in Frederick, Maryland, the 275,000ft2 facility will produce the FDA-approved CAR T-cell therapy which is utilised for the treatment of blood cancer. The CAR T-cell therapies are

As part of the collaboration, the companies will jointly develop new antibody drugs which can significantly expand the immunotherapy’s potential in improving the lives of cancer and other

The clinical trial is designed for assessing GRC 54276’s tolerability and safety as a monotherapy, as well as in combination with checkpoint inhibitors in these patients. GRC 54276

Upon receiving approval, the human monoclonal antibody Dupixent will be the first medicine available in the US for the treatment of eosinophilic esophagitis (EoE). It is designed to

The company intends to utilise the funds to continue its ongoing Phase Ib clinical trial and begin two additional Phase Ib studies this year. It also plans to